Clinical trials located in

Garches

Garches city is located in France. Currently, 8 clinical trials are being conducted in this city.

Garches, located in the Hauts-de-Seine department in France, is a city known for its rich history and architectural heritage. Nestled in the western suburbs of Paris, it boasts the Saint-Louis Hospital, designed by the renowned architect Léon Azéma. Garches is also home to the Raymond Poincaré Hospital, a leading center for physical rehabilitation. The city’s landscape is characterized by its lush green spaces, including the Parc de Saint-Cloud, offering residents and visitors a serene environment. Garches has a vibrant community life, with cultural and sporting events throughout the year.

  • CT-EU-00111939

    Exploring the safety and effects of SQY51 in Duchenne Muscular Dystrophy Patients

    The Avance1 study is being launched to evaluate the safety and efficacy of SQY51, a novel treatment for Duchenne Muscular Dystrophy. Initially, the study will undergo a 13-week Phase 1 to optimize the dosage for balance between safety and effectiveness, followed by a 32-week Phase 2a to assess the effects of varying doses. SQY51 will be administered via intravenous infusion. The trial aims to ensure participant safety while exploring the potential benefits of SQY51 for both children and adults diagnosed with this condition.  Participation is sought from those with a confirmed diagnosis, aiming to enlist 12 participants.

    • SQY51-new potential treatment for Duchenne Muscular Dystrophy
  • Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    • gefurulimab/ALXN1720
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing venglustat for heart condition in Fabry disease patients

    This study is about a medicine called venglustat, and how it affects the size of the left side of the heart for people with a disease called Fabry. The trial will have men and women with Fabry disease, who will either get venglustat or the current commonly used treatments. The aim is to investigate whether venglustat can induce changes in the size of the left side of the hearts. The trial will last for 18 months, with check-ups every 3 to 6 months. After the first 18 months, patients can choose to get venglustat for 34 more months. So, the whole study could last up to 4.4 years for some people.

    • Agalsidase beta/GZ419828
    • Venglusat/GZ402671
    • Agalsidase alfa
    • Migalastat
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France:

.